Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

The University of Chicago will receive up to $130 million in funding over the next 10 years as part of a new drug research ...

SAN DIEGO - Dare Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has been awarded a Notice of Award of a grant from the National Institute of Allergy and ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

The total consideration to acquire 100 percent of the issued share capital by Biotheus amounts to $800 million, predominantly in cash, with a small portion in BioNTech American Depositary Shares, plus ...